168 related articles for article (PubMed ID: 9726086)
41. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Wiseman LR; Markham A
Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
[TBL] [Abstract][Full Text] [Related]
42. Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
Aravantinos G; Skarlos DV; Kosmidis P; Georgoulias V; Sgouros I; Bafaloukos D; Androulakis N; Florou S; Fountzilas G
Crit Rev Oncol Hematol; 1999 Dec; 32(3):209-19. PubMed ID: 10633850
[No Abstract] [Full Text] [Related]
43. A risk-benefit assessment of irinotecan in solid tumours.
Siu LL; Rowinsky EK
Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
[TBL] [Abstract][Full Text] [Related]
44. [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
Yanagisawa M; Ishikawa T; Ouchi KF; Tanaka Y
Gan To Kagaku Ryoho; 2003 Feb; 30(2):223-30. PubMed ID: 12610870
[TBL] [Abstract][Full Text] [Related]
45. FDA approves irinotecan as first-line therapy for colorectal cancer.
Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
[No Abstract] [Full Text] [Related]
46. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Mitry E; Douillard JY; Van Cutsem E; Cunningham D; Magherini E; Mery-Mignard D; Awad L; Rougier P
Ann Oncol; 2004 Jul; 15(7):1013-7. PubMed ID: 15205193
[TBL] [Abstract][Full Text] [Related]
47. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.
Kramar A; Gourgou-Bourgade S; Ychou M
J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517
[No Abstract] [Full Text] [Related]
48. [Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Petrasch S; Dörr T; Kemmeries G
Z Gastroenterol; 1999 Jun; 37(6):575-7. PubMed ID: 10427662
[No Abstract] [Full Text] [Related]
49. Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
Desai AA; Kindler HL; Taber D; Agamah E; Mani S; Wade-Oliver K; Ratain MJ; Vokes EE
Cancer Chemother Pharmacol; 2005 Oct; 56(4):421-6. PubMed ID: 15895230
[TBL] [Abstract][Full Text] [Related]
50. Irinotecan: a new antineoplastic agent for the management of colorectal cancer.
Cersosimo RJ
Ann Pharmacother; 1998 Dec; 32(12):1324-33. PubMed ID: 9876815
[TBL] [Abstract][Full Text] [Related]
51. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
Schoemaker NE; Kuppens IE; Moiseyenko V; Glimelius B; Kjaer M; Starkhammer H; Richel DJ; Smaaland R; Bertelsen K; Poulsen JP; Voznyi E; Norum J; Fennelly D; Tveit KM; Garin A; Gruia G; Mourier A; Sibaud D; Lefebvre P; Beijnen JH; Schellens JH; ten Bokkel Huinink WW
Br J Cancer; 2004 Oct; 91(8):1434-41. PubMed ID: 15381932
[TBL] [Abstract][Full Text] [Related]
52. Irinotecan: promising activity in the treatment of malignant glioma.
Reardon DA; Friedman HS; Powell JB; Gilbert M; Yung WK
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):9-14. PubMed ID: 12800600
[TBL] [Abstract][Full Text] [Related]
53. Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Goldberg RM; O'Neil BH
Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):507-9. PubMed ID: 19713983
[TBL] [Abstract][Full Text] [Related]
54. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
Di Paolo A; Bocci G; Danesi R; Del Tacca M
Curr Clin Pharmacol; 2006 Sep; 1(3):311-23. PubMed ID: 18666754
[TBL] [Abstract][Full Text] [Related]
55. In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
Yamashita K; Urakami A; Kubozoe T; Ikeda M; Hirabayashi Y; Yamamura M; Iki K; Akiyama T; Matsumoto H; Hirai T; Sadahira Y; Tsunoda T
Int J Clin Oncol; 2005 Oct; 10(5):328-32. PubMed ID: 16247659
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and tolerability of irinotecan in patients with advanced colorectal cancer in Singapore.
See HT; Koo WH; Ang P; Au E; Ang PT
Ann Acad Med Singap; 2002 Sep; 31(5):651-5. PubMed ID: 12395655
[TBL] [Abstract][Full Text] [Related]
57. Two schedules of second-line irinotecan for metastatic colon carcinoma.
Earle CC; Kwok A; Gazelle GS; Fuchs CS
Cancer; 2004 Dec; 101(11):2533-9. PubMed ID: 15503310
[TBL] [Abstract][Full Text] [Related]
58. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Berg D
Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
[TBL] [Abstract][Full Text] [Related]
59. Alternative dosing schedules for irinotecan.
Rothenberg ML; Kuhn JG; Schaaf LJ; Drengler RL; Eckhardt SG; Villalona-Calero MA; Hammond L; Miller LL; Petit RG; Rowinsky EK; Von Hoff DD
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):68-71. PubMed ID: 9726095
[TBL] [Abstract][Full Text] [Related]
60. Irinotecan in the management of patients with pancreatic cancer.
Green MR; Harper M; Safa A; Sherman CA; Mushtaq CM; Bahadori H; Brescia FJ; Rocha Lima CM
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):31-3. PubMed ID: 11200146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
